Literature DB >> 21625079

Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis.

Liu Liwei1, Liu Chunyu, Li Jie, Han Ruifa.   

Abstract

OBJECTIVES: To examine the association between fibroblast growth factor receptor-4 (FGFR-4) genetic polymorphisms (Gly-388Arg) and prostate cancer susceptibility.
METHODS: A comprehensive search was conducted to identify all case-control studies of FGFR-4 polymorphisms and prostate cancer risk. Statistical analysis was performed with the software program Stata, version 8.0, and Review Manage, version 4.2.
RESULTS: A total of 4 eligible studies, including 2,618 cases and 2,305 controls, relating the FGFR-4 polymorphism to the risk of prostate cancer were identified. The overall results indicated a significant association between FGFR-4 polymorphisms and prostate cancer. In the subgroup analysis by ethnicity, a significant association was found between European descent for recessive model (random effects OR 0.82, 95% CI 0.72-0.93) and co-dominant genetic model (random effects OR 0.83, 95% CI 0.68-1.00). Sensitivity analysis also found a significant association in the recessive (random effects OR 0.68, 95% CI 0.49-0.95) or the co-dominant (random effects OR 0.68, 95% CI 0.49-0.96) models. Egger's test showed that publication bias was not present in any of the comparisons.
CONCLUSIONS: Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21625079     DOI: 10.1159/000329069

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  The rs1050450 C > T polymorphism of GPX1 is associated with the risk of bladder but not prostate cancer: evidence from a meta-analysis.

Authors:  Tongyi Men; Xiaoming Zhang; Jiwei Yang; Bin Shen; Xianduo Li; Dongdong Chen; Jianning Wang
Journal:  Tumour Biol       Date:  2013-08-23

Review 2.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

3.  Association between genetic variants in glutathione peroxidase 1 gene and risk of prostate cancer: a meta-analysis.

Authors:  Liu Liwei; Zhang Wei; Han Ruifa; Liu Chunyu
Journal:  Mol Biol Rep       Date:  2012-06-15       Impact factor: 2.316

4.  FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.

Authors:  Hong-mei Fang; Gang Tian; Li-juan Zhou; Han-ying Zhou; Ying-zhi Fang
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

5.  FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.

Authors:  Roberta Lelis Dutra; Marcos Brasilino de Carvalho; Marcelo Dos Santos; Ana Maria da Cunha Mercante; Diana Gazito; Rafael de Cicco; Gencapo Group; Eloiza Helena Tajara; Iúri Drumond Louro; Adriana Madeira Álvares da Silva
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

6.  Role of genetic & environment risk factors in the aetiology of colorectal cancer in Malaysia.

Authors:  Nurul Hanis Ramzi; Jagdish Kaur Chahil; Say Hean Lye; Khamsigan Munretnam; Kavitha Itagi Sahadevappa; Sharmila Velapasamy; Nikman Adli Nor Hashim; Soon Keat Cheah; Gerard Chin Chye Lim; Heselynn Hussein; Mohd Roslan Haron; Livy Alex; Lian Wee Ler
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.